California Public Employees Retirement System Has $4.90 Million Stake in Bruker Corporation $BRKR

California Public Employees Retirement System cut its holdings in Bruker Corporation (NASDAQ:BRKR) by 27.5% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 135,653 shares of the medical research company’s stock after selling 51,544 shares during the quarter. California Public Employees Retirement System’s holdings in Bruker were worth $4,900,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Allworth Financial LP raised its position in Bruker by 40.6% during the third quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock worth $29,000 after acquiring an additional 257 shares in the last quarter. Federated Hermes Inc. raised its holdings in shares of Bruker by 6.7% in the 4th quarter. Federated Hermes Inc. now owns 6,027 shares of the medical research company’s stock valued at $284,000 after purchasing an additional 380 shares during the period. Parallel Advisors LLC lifted its stake in Bruker by 121.0% in the 4th quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock valued at $41,000 after purchasing an additional 479 shares during the last quarter. State of Michigan Retirement System lifted its stake in Bruker by 1.9% in the 1st quarter. State of Michigan Retirement System now owns 26,693 shares of the medical research company’s stock valued at $964,000 after purchasing an additional 500 shares during the last quarter. Finally, CWM LLC grew its holdings in Bruker by 49.8% during the fourth quarter. CWM LLC now owns 1,631 shares of the medical research company’s stock worth $77,000 after purchasing an additional 542 shares during the period. 79.52% of the stock is owned by institutional investors.

Bruker Price Performance

Shares of BRKR opened at $60.45 on Monday. The firm has a market cap of $9.20 billion, a P/E ratio of -251.88, a price-to-earnings-growth ratio of 1.94 and a beta of 1.29. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.72 and a current ratio of 1.55. Bruker Corporation has a 52 week low of $28.53 and a 52 week high of $64.54. The firm’s 50-day simple moving average is $56.32 and its 200 day simple moving average is $46.29.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings data on Wednesday, May 6th. The medical research company reported $0.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.23 by $0.08. Bruker had a negative net margin of 0.65% and a positive return on equity of 11.60%. The firm had revenue of $823.40 million during the quarter, compared to the consensus estimate of $795.62 million. During the same period last year, the business posted $0.47 earnings per share. The business’s revenue for the quarter was up 2.7% compared to the same quarter last year. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, analysts forecast that Bruker Corporation will post 2.12 earnings per share for the current year.

Bruker Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, July 7th. Investors of record on Monday, June 22nd were issued a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend was Monday, June 22nd. Bruker’s dividend payout ratio (DPR) is presently -83.33%.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. Barclays boosted their price target on Bruker from $53.00 to $60.00 and gave the stock an “overweight” rating in a research report on Wednesday, June 24th. Wolfe Research initiated coverage on Bruker in a research report on Monday, June 1st. They issued a “peer perform” rating for the company. Guggenheim lifted their target price on Bruker from $50.00 to $70.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. Citigroup boosted their target price on Bruker from $44.00 to $60.00 and gave the stock a “neutral” rating in a report on Wednesday, July 8th. Finally, Weiss Ratings upgraded Bruker from a “sell (d)” rating to a “sell (d+)” rating in a research note on Wednesday, June 3rd. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $56.79.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.